Abstracts tagged "Genomics and Proteomics"

Abstract Number: 0946 • ACR Convergence 2024
Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations
Yidan Wang¹, Jessica Maciuch², Tyler Therron³, Carla Cuda², Deborah Winter⁴ and Harris Perlman², ¹Northwestern University, Hanover Park, IL, ²Northwestern University, Chicago, IL, ³Northwestern University, Chicago, ⁴Northwestern University, Skokie, IL
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…
Abstract Number: 1589 • ACR Convergence 2024
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Philip Yee³, Emma Derrett-Smith⁴, Voon Ong⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³UCL, London, United Kingdom, ⁴University College London Division of Medicine, Birmingham, United Kingdom, ⁵University College London, London, England, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement. We have asked whether whole skin gene expression may…
Abstract Number: 1660 • ACR Convergence 2024
Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals
Mark Gillespie¹, Ziyuan He¹, Adam Savage¹, Pravina Venkatesan¹, Marla Glass¹, Lauren Okada², Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Christy Bennett¹, Julian Reading², Jessica Garber², Palak Genge², Veronica Hernandez², Alexander Heubeck², Erin Kawelo², Upaasana Krishnan², Kevin Lee², Regina Mettey², Blessing Musgrove², Vaishnavi Parthasarathy², Cole Phalen², Charles Roll², Tyanna Stuckey², Morgan Weiss¹, Claire Gustafson², Qiuyu Gong², Emma Kuan², Tao Peng², Lucas Graybuck², Kristen Demoruelle³, Kristine Kuhn⁴, David Boyle⁵, Fan Zhang⁴, Thomas Bumol⁶, Ananda Goldrath², Xiaojun Li¹, V. Michael Holers⁷, Peter Skene¹, Gary Firestein⁸, Kevin Deane⁹ and Troy Torgerson¹⁰, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³University of Colorado Anschutz Medical Campus, Golden, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶Allen Institute for Immunology, San Diego, CA, ⁷University of Colorado, Denver, CO, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Mireia Lopez Corbeto¹, yolanda Guillen², Irene Bonafonte³, Nuria Palau⁴, Raül Tortosa⁴, Estefanía Moreno Ruzafa¹, Antonio Julia⁵ and Sara Marsal⁶, ¹Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Berufserfahrung: Helmholtz Munich, Barcelona, Spain, ⁴Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ⁵Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁶Vall Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Carol Nassar¹, Rene Quevedo², M. Teresa Ciudad², Zoha Faheem³, Kieran Manion⁴, Carolina Munoz-Grajales⁵, Michael Kim⁶, Dafna Gladman⁷, Murray Urowitz⁸, Zahi Touma¹, Tracy McGaha⁹ and Joan Wither⁶, ¹University of Toronto, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵UHN/TWH, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Self employed, Toronto, ON, Canada, ⁹University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Ignacio Rego-Perez¹, Alejandro Duran-Sotuela², Jorge Vazquez-Garcia², Cristina Ruiz-Romero³, Valentina Calamia², Carlota Fraga-Seijas⁴, Vanesa Balboa-Barreiro⁵, Sara Relaño², María C. De Andrés², Lucia Lourido², Rocio Paz-Gonzalez², Patricia Quaranta², Patricia Fernández-Puente², Nicola Veronese⁶, Natividad Oreiro⁷ and francisco J Blanco⁸, ¹Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, ³INIBIC - CHUAC, A Coruña, Spain, ⁴INIBIC, A Coruña, Spain, ⁵Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁶Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, ⁷CHUAC, La Coruna, Galicia, Spain, ⁸INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…
Abstract Number: 2418 • ACR Convergence 2024
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Matthew Linnik¹, Guilherme Rocha², David Gemperline³, Ernst Dow³, Christoph Preuss³, Helen Masson⁴, Olivia Ellis⁴, Ana Accioly³, Maja Hojnik⁵, Kira Rubtsova¹, Robert Benschop⁶, Mark Chambers⁷, Mark Genovese³ and Richard Higgs³, ¹Eli Lilly, San Diego, CA, ²Eli Lilly, Indianapolis, IN, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly and Co, San Diego, CA, ⁵Eli Lilly and Co., Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Zionsville, IN
Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
Abstract Number: 2425 • ACR Convergence 2024
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Marianna Rowlands¹, Thomas Dörner², Diego Saldana Miranda³, Justin McMullen³, Aida Santos da Costa³, Ulrike Sommer³, Rainer Hillenbrand³, Andre Nogueira da Costa³, Claire Bonal³, Isabelle Isnardi³, Edward Khokhlovich¹ and Stephen J Oliver³, ¹Biomedical Research, Novartis, Cambridge, MA, ²Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736), a B cell activating factor receptor (BAFFR) targeting mAb, depletes B cells via both antibody dependent cellular cytotoxicity and blockade of BAFF:BAFFR…
Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Emma Derrett-Smith³, Voon Ong⁴, Christopher Buckley⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³University College London Division of Medicine, Birmingham, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…
Abstract Number: 0778 • ACR Convergence 2024
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Justin Chou¹, Ricardo Grieshaber-Bouyer², Michelle J Wu³, Christina Bergmann², Jule Taubmann⁴, Fabian Müller⁵, Aline Bozec⁴, Tobias Rothe², Andreas MAckensen⁶, Amber Podoll⁷, Jonathan Gutman⁷, Aiden Haghikia⁸, Dimitrios Mougiakakos⁹, Gary Tong³, Pouya Kheradpour³, Francis Kim¹⁰, Prameela Ramesan¹⁰, Brandon Kwong¹⁰, Kunbin Qu¹⁰, Bishwa Ganguly¹⁰, Dominic Borie¹⁰, James Chung¹⁰ and Georg Schett¹¹, ¹Kyverna Therapeutics, Emeryville, CA, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Verily Life Sciences, South San Francisco, CA, ⁴Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO, ⁸Otto-von-Guericke University, Magdeburg, Germany, ⁹Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, ¹⁰Kyverna Therapeutics, Inc., Emeryville, CA, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
Abstract Number: 0892 • ACR Convergence 2024
Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Tommi C. Taylor¹, Sri Ramarathinam², Shan Zou Chung², Kirti Pandey², Ananth Aditya Jupudi¹, Bhuwan Khatri³, Sherri Longobardi³, Charmaine Lopez-Davis³, Astrid Rasmussen³, Kiely Grundahl³, Robert Hal Scofield³, Christopher Lessard³, Linda F. Thompson³, Anthony W. Purcell² and A. Darise Farris³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Monash University, Clayton, Victoria, Australia, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
Abstract Number: 0893 • ACR Convergence 2024
Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response
Ismael Sánchez Pareja¹, Carlos Perez-Sanchez¹, Dani Toro-Domínguez², Laura Muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño³, Rafaela Ortega-Castro⁴, Jerusalem Calvo Gutierrez⁵, María Lourdes Ladehesa-Pineda⁶, Concepción Aranda-Valera³, María Carmen Ábalos-Aguilera⁷, Christian Merlo-Ruiz⁷, Mª Angeles Aguirre-Zamorano⁸, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁶, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Fundación Progreso y Salud, Andalusian Government, Granada, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁵HU Reina Sofia, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Characterize the molecular landscape of RA patients using a multi-omic approach encompassing transcriptomics and proteomics and assess its association with disease stage and therapeutic…
Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].